Inventiva S.A. Sponsored ADR (NASDAQ:IVA – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $3.31 and last traded at $3.2460, with a volume of 194757 shares trading hands. The stock had previously closed at $3.45.
Analysts Set New Price Targets
A number of equities research analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research note on Friday, July 17th. Piper Sandler reissued an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Guggenheim raised their price objective on shares of Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Finally, Cantor Fitzgerald began coverage on shares of Inventiva in a research note on Friday, July 17th. They set an “overweight” rating on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $15.75.
View Our Latest Stock Report on Inventiva
Inventiva Trading Down 7.4%
Hedge Funds Weigh In On Inventiva
Hedge funds and other institutional investors have recently modified their holdings of the stock. Engineers Gate Manager LP increased its holdings in Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after acquiring an additional 43,280 shares during the last quarter. Persistent Asset Partners Ltd bought a new position in shares of Inventiva during the 4th quarter valued at about $603,000. Seven Fleet Capital Management LP bought a new position in shares of Inventiva during the 1st quarter valued at about $1,111,000. Eventide Asset Management LLC purchased a new position in shares of Inventiva during the fourth quarter valued at about $1,155,000. Finally, Propel Bio Management LLC purchased a new position in shares of Inventiva during the fourth quarter valued at about $4,650,000. Institutional investors own 19.06% of the company’s stock.
About Inventiva
Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.
Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.
Read More
- Five stocks we like better than Inventiva
- Meta One Subscriptions Show Positive Early Signs, Analysts Forecast Long-Term Growth
- Is the Market Right or Wrong About These 4 High Short Interest Stocks?
- Power Play: Vistra Powers New Era’s AI Data Center Deal
- Treasury Yields Hit a 19-Year High—These 2 Bond ETFs Offer Monthly Income
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.
